Picture of FamiCord AG logo

V3V FamiCord AG Share Price

0.000.00%
de flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapNeutral

Momentum

Relative Strength (%)
1m+6.21%
3m+2.54%
6m-6.09%
1yr-17.41%
Volume Change (%)
10d/3m+103.88%
Price vs... (%)
52w High-21.9%
50d MA+0.36%
200d MA-4.06%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-0.54%
Return on Equity14.16%
Operating Margin-0.72%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of FamiCord AG EPS forecast chart

Profile Summary

FamiCord AG, formerly Vita 34 AG, is a Germany-based company operating in the medical technology sector and acts as a cell bank/stem bank. The Company is involved in the long-term storage and processing of stem cells from human umbilical cord blood. The cells are collected during the child’s birth and can be used later in his or her life for the treatment of many diseases, such as anemia, diabetes, degenerative joint diseases, cancer, neurological deficits after brain injuries, cartilage damages and others. The cells also allow the growing of whole organs, such as the liver. On an average, one out of seven individuals, whose cells are sorted, receives autologous stem cell transplant by age of 70. The Company acts as a cord blood bank and is also engaged in research activities around regenerative medicine, including curing the consequences of strokes and heart attacks. The Company operates in Germany, Spain and Denmark.

Directors

Last Annual
December 31st, 2023
Last Interim
September 30th, 2024
Incorporated
January 19th, 2004
Public Since
November 21st, 2007
No. of Employees
758
Sector
Healthcare Providers & Services
Industry
Healthcare
Exchange
de flag iconXETRA
Shares in Issue
17,431,762
Blurred out image of a map
Address
Perlickstrasse 5, LEIPZIG, 04103
Web
https://www.famicord.com/
Phone
+49 341487925500
Contact
Jakub Baran
Auditors
PricewaterhouseCoopers GmbH

V3V Share Price Performance

Upcoming Events for V3V

Q4 2024 Vita 34 AG Earnings Release

Q1 2025 Vita 34 AG Earnings Release

Vita 34 AG Annual Shareholders Meeting

Vita 34 AG Annual Shareholders Meeting

Q2 2025 Vita 34 AG Earnings Release

FAQ